Commonality of the IL-4/IL-13 pathway in atopic diseases

Expert Review of Clinical Immunology

Volumn 13, Issue 5, 2017, Pages 425-437

  Gandhi, Namita A ^a   Pirozzi, Gianluca ^b   Graham, Neil M H ^a  

^a REGENERON PHARMACEUTICALS INC   (United States)

^b SANOFI   (France)

Author keywords

asthma; atopic dermatitis; dupilumab; interleukin 13; interleukin 4; lebrikizumab; nasal polyposis; tralokinumab; Type 2 pathway

Indexed keywords

DUPILUMAB; IMMUNOGLOBULIN E; INTERLEUKIN 13; INTERLEUKIN 4; OMALIZUMAB; ALLERGEN;

ASTHMA; ATOPIC DERMATITIS; BIOLOGICAL THERAPY; BODY SURFACE; CHRONIC SINUSITIS; COMORBIDITY; DENDRITIC CELL; DISEASE ASSOCIATION; ENVIRONMENTAL FACTOR; EOSINOPHIL; GENE MUTATION; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LICHENOID ERUPTION; MAST CELL; NOSE POLYP; OSTEOLYSIS; PHENOTYPE; PREVALENCE; QUALITY OF LIFE; REVIEW; SIGNAL TRANSDUCTION; TH2 CELL; THERAPY EFFECT; TREATMENT RESPONSE; CHRONIC DISEASE; IMMUNOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; SINUSITIS;

ALLERGENS; ASTHMA; CHRONIC DISEASE; DERMATITIS, ATOPIC; HUMANS; INTERLEUKIN-13; INTERLEUKIN-4; MOLECULAR TARGETED THERAPY; NASAL POLYPS; SIGNAL TRANSDUCTION; SINUSITIS; TH2 CELLS;

EID: 85018324268     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1080/1744666X.2017.1298443     Document Type: Review

References (134)

1. Wynn TA., Type 2 cytokines:mechanisms and therapeutic strategies. Nat Reviews Immunol. 2015;15:271–282.
2. Kay AB. Allergy and allergic diseases. Second of two parts. N Engl J Med. 2001;344:109–113.
3. Palm NW, Rosenstein RK, Medzhitov R. Allergic host defences. Nature. 2012;484:465–472.
4. Gough H, Grabenhenrich L, Reich A, et al.; group MASs. Allergic multimorbidity of asthma, rhinitis and eczema over 20 years in the German birth cohort MAS. Pediatr Allergy Immunol. 2015;26:431–437.
5. Eriksson J, Bjerg A, Lotvall J, et al. Rhinitis phenotypes correlate with different symptom presentation and risk factor patterns of asthma. Respir Med. 2011;105:1611–1621.
6. Thomsen SF. Epidemiology and natural history of atopic diseases. Eur Respir J. 2015;2:24642.
7. Durham SR, Creticos PS, Nelson HS, et al. Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis:pooled analyses. J Allergy Clin Immunol. 2016;138:1081–8.e4. Epub 2016/08/17.• Meta-analysis of efficacy of several anti-allergy therapies.
8. Normansell R, Walker S, Milan SJ, et al. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014;1:Cd003559. Epub 2014/01/15.
9. Chauhan BF, Ducharme FM. Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma. Cochrane Database Syst Rev. 2014:Cd003137. Epub 2014/01/25.
10. Cabon Y, Molinari N, Marin G, et al. Comparison of anti-interleukin-5 therapies in patients with severe asthma:global and indirect meta-analyses of randomized placebo-controlled trials. Clin Exp Allergy. 2017;47:129–138. Epub 2016/11/20.
11. Heil PM, Maurer D, Klein B, et al. Omalizumab therapy in atopic dermatitis:depletion of IgE does not improve the clinical course - a randomized, placebo-controlled and double blind pilot study. J Dtsch Dermatol Ges. 2010;8:990–998.• Results from clinical study demonstrating that anti-IgE was not effective in atopic dermatitis.
12. Powell C, Milan SJ, Dwan K, et al. Mepolizumab versus placebo for asthma. Cochrane Database Syst Rev. 2015;7:Cd010834. Epub 2015/07/28.
13. Oldhoff JM, Darsow U, Werfel T, et al. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy. 2005;60:693–696.• Results from clinical study demonstrating that anti-IL-5 was not effective in atopic dermatitis.
14. Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis:section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermat. 2014;70:338–351.
15. Gandhi NA, Bennett BL, Graham NM, et al. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15:35–50.
16. Swain SL, Weinberg AD, English M, et al. IL-4 directs the development of Th2-like helper effectors. J Immunol (Baltimore, Md:1950). 1990;145:3796–3806.
17. Howard M, Farrar J, Hilfiker M, et al. Identification of a T cell-derived b cell growth factor distinct from interleukin 2. J Exp Med. 1982;155:914–923.
18. Gascan H, Gauchat JF, Aversa G, et al. Anti-CD40 monoclonal antibodies or CD4+ T cell clones and IL-4 induce IgG4 and IgE switching in purified human B cells via different signaling pathways. J Immunol (Baltimore, Md:1950). 1991. Epub 1991/07/01.
19. Webb DC, McKenzie AN, Koskinen AM, et al. Integrated signals between IL-13, IL-4, and IL-5 regulate airways hyperreactivity. J Immunol (Baltimore, Md:1950). 2000;165:108–113.
20. Rosenberg HF, Phipps S, Foster PS. Eosinophil trafficking in allergy and asthma. J Allergy Clin Immunol. 2007;119:1303-10; quiz 11-2.
21. Kopf M, Le Gros G, Bachmann M, et al. Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature. 1993;362:245–248.
22. McKenzie AN, Culpepper JA, De Waal Malefyt R, et al. Interleukin 13, a T-cell-derived cytokine that regulates human monocyte and B-cell function. Proc Natl Acad Sci U S A. 1993;90:3735–3739.
23. Cockcroft DW, Davis BE. Mechanisms of airway hyperresponsiveness. J Allergy Clin Immunol. 2006;118:551-9;quiz 60-1.
24. Katial RK, Covar RA. Bronchoprovocation testing in asthma. Immunol Allergy Clin North Am. 2012;32:413–431.
25. Wills-Karp M, Luyimbazi J, Xu X, et al. Interleukin-13:central mediator of allergic asthma. Science. 1998;282:2258–2261.
26. Russell SM, Keegan AD, Harada N, et al. Interleukin-2 receptor gamma chain:a functional component of the interleukin-4 receptor. Science New York, NY. 1993;262:1880–1883.
27. Chatila TA. Interleukin-4 receptor signaling pathways in asthma pathogenesis. Trends Mol Med. 2004;10:493–499.
28. LaPorte SL, Juo ZS, Vaclavikova J, et al. Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system. Cell. 2008;132:259–272.•• Structural insights on binding properties of IL-4 and IL-13 to their respective receptors.
29. Lowenthal JW, Castle BE, Christiansen J, et al. Expression of high affinity receptors for murine interleukin 4 (BSF-1) on hemopoietic and nonhemopoietic cells. J Immunol (Baltimore, Md:1950). 1988;140:456–464.
30. Akaiwa M, Yu B, Umeshita-Suyama R, et al. Localization of human interleukin 13 receptor in non-haematopoietic cells. Cytokine. 2001;13:75–84.
31. Morrison BE, Marcondes MC, Nomura DK, et al. Cutting edge:IL-13Ralpha1 expression in dopaminergic neurons contributes to their oxidative stress-mediated loss following chronic peripheral treatment with lipopolysaccharide. J Immunol (Baltimore, Md:1950). 2012;189:5498–5502.
32. Arima K, Sato K, Tanaka G, et al. Characterization of the interaction between interleukin-13 and interleukin-13 receptors. J Biol Chem. 2005;280:24915–24922. Epub 2005/05/05.
33. Kawakami K, Kawakami M, Snoy PJ, et al. In vivo overexpression of IL-13 receptor alpha2 chain inhibits tumorigenicity of human breast and pancreatic tumors in immunodeficient mice. J Exp Med. 2001;194:1743–1754.
34. May RD, Fung M. Strategies targeting the IL-4/IL-13 axes in disease. Cytokine. 2015;75:89–116.
35. Reichert P, Reinhardt RL, Ingulli E, et al. Cutting edge:in vivo identification of TCR redistribution and polarized IL-2 production by naive CD4 T cells. J Immunol (Baltimore, Md:1950). 2001;166:4278–4281.
36. Poo WJ, Conrad L, Janeway CA, Jr. Receptor-directed focusing of lymphokine release by helper T cells. Nature. 1988;332:378–380.
37. Kupfer H, Monks CR, Kupfer A. Small splenic B cells that bind to antigen-specific T helper (Th) cells and face the site of cytokine production in the Th cells selectively proliferate:immunofluorescence microscopic studies of Th-B antigen-presenting cell interactions. J Exp Med. 1994;179:1507–1515.
38. Brandt EB, Sivaprasad U. Th2 cytokines and atopic dermatitis. J Clin Cell Immunol. 2011;2:110.
39. Fahy JV. Type 2 inflammation in asthma–present in most, absent in many. Nat Reviews Immunol. 2015;15:57–65.
40. Borish LC, Nelson HS, Corren J, et al. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol. 2001;107:963–970.
41. Hart TK, Blackburn MN, Brigham-Burke M, et al. Preclinical efficacy and safety of pascolizumab (SB 240683):a humanized anti-interleukin-4 antibody with therapeutic potential in asthma. Clin Exp Immunol. 2002;130:93–100.
42. Gauvreau GM, Boulet LP, Cockcroft DW, et al. The effects of IL-13 blockade on allergen-induced airway responses in mild atopic asthma. Am J Respir Crit Care Med. 2010:Epub 2010/11/09.
43. Ultsch M, Bevers J, Nakamura G, et al. Structural basis of signaling blockade by anti-IL-13 antibody Lebrikizumab. J Mol Biol. 2013;425:1330–1339.• Structural analysis showing that lebrikizumab blocks signaling of IL-13 by blocking binding to IL-4Rα.
44. Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011;365:1088–1098.•• Results from clinical study showing that anti-IL-13 treatment improves lung function in patient with severe asthma and in a subset identified by biomarkers of Type 2 immune activation.
45. Brightling CE, Chanez P, Leigh R, et al. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma:a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med. 2015;3:692–701. Epub 2015/08/02.•• Results from Phase 2b clinical study showing that 52 weeks of anti-IL-13 treatment with tralokinumab did not reduce asthma exacerbation in patients with severe asthma.
46. Walsh GM. Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD. Curr Opin Investig Drugs. 2010;11:1305–1312.
47. Economides AN, Carpenter LR, Rudge JS, et al. Cytokine traps:multi-component, high-affinity blockers of cytokine action. Nat Med. 2003;9:47–52.
48. Groves RW, Wilbraham D, Fuller R, et al. Inhibition of IL-4 and IL-13 with an IL-4 mutein (Aeroderm) protects against flares in atopic eczema. J Invest Dermatol. 2007;127:S54.
49. Wenzel SE, Ind PW, Otulana BA, et al. Inhaled pitrakinra, an IL-4/IL-13 antagonist reduces exacberbations in patients with eosinophilic asthma. Barcelona, Spain:Publisher; 2010.
50. Corren J, Busse W, Meltzer EO, et al. A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. Am J Respir Crit Care Med. 2010;181:788–796.• Results from clinical study showing that 12 weeks of IL-4R blockade with AMG317 did not improve asthma control questionnaire.
51. Kakkar T, Sung C, Gibiansky L, et al. Population PK and IgE pharmacodynamic analysis of a fully human monoclonal antibody against IL4 receptor. Pharm Res. 2011;28:2530–2542.• Pharmacodynamics analysis of AMG317 and insights on antibody pharmacokinetics properties.
52. Simpson EL, Bieber T, Guttman-Yassky E, et al.; Solo, Investigators S. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375:2335–2348.•• Results from two Phase 3 clinical studies showing that IL-4R blockade with dupilumab reduces disease activity in atopic dermatitis.
53. Beck LA, Thaci D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371:130–139.•• Results from early phase clinical studies showing efficacy of IL-4R blockade with dupilumab atopic dermatitis.
54. Thaci D, Simpson EL, Beck LA, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments:a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2016;387:40–52.• Results from dose-ranging study with dupilumab in atopic dermatitis.
55. Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368:2455–2466.•• Proof-of-concept study demonstrating the efficacy of IL-4R blockade with dupilumab in asthmatics with high blood eosinophils.
56. Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist:a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388:31–44.•• Phase 2b dose-ranging clinical study demonstrating the efficacy of IL-4R blockade with dupilumab in severe asthmatics regardless of blood eosinophil subgroup.
57. Bachert C, Mannent L, Naclerio RM, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis:a randomized clinical trial. JAMA. 2016;315:469–479.•• Proof-of-concept study demonstrating efficacy of IL-4R blockade with dupilumab in patients with chronic sinusitis with nasal polyposis and comorbid asthma.
58. Chaker AM, Shamji MH, Dumitru FA, et al. Short-term subcutaneous grass pollen immunotherapy under the umbrella of anti-IL-4:A randomized controlled trial. J Allergy Clin Immunol. 2016;137:452–61.e9. Epub 2015/11/05.
59. Simpson EL, Bieber T, Eckert L, et al. Patient burden of moderate to severe atopic dermatitis (AD):insights from a phase 2b clinical trial of dupilumab in adults. J Am Acad Dermatol. 2016;74:491–498.• Study showing characterization of disease burden in adult atopic dermatitis.
60. DaVeiga SP. Epidemiology of atopic dermatitis:a review. Allergy Asthma Proc. 2012;33:227–234. Epub 2012/05/16.
61. Drucker AM, Wang AR, Li WQ, et al. The burden of atopic dermatitis:summary of a report for the national eczema association. J Invest Dermatol. 2017;137:26–30.
62. Irvine AD, McLean WH, Leung DY. Filaggrin mutations associated with skin and allergic diseases. N Engl J Med. 2011;365:1315–1327.
63. Lubbe J. Secondary infections in patients with atopic dermatitis. Am J Clin Dermatol. 2003;4:641–654.
64. Gong JQ, Lin L, Lin T, et al. Skin colonization by Staphylococcus aureus in patients with eczema and atopic dermatitis and relevant combined topical therapy:a double-blind multicentre randomized controlled trial. Br J Dermatol. 2006;155:680–687.
65. Boguniewicz M, Leung DY. Atopic dermatitis:a disease of altered skin barrier and immune dysregulation. Immunol Rev. 2011;242:233–246.
66. Leung DY. New insights into atopic dermatitis:role of skin barrier and immune dysregulation. Allergol International. 2013;62:151–161.
67. Bieber T. Atopic dermatitis. N Engl J Med. 2008;358:1483–1494.
68. Gittler JK, Shemer A, Suarez-Farinas M, et al. Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol. 2012;130:1344–1354.• Analysis of the molecular factors of acute and chronic AD lesions demonstrating intensification of TH2, TH1 and TH22 inflammation.
69. Kiehl P, Falkenberg K, Vogelbruch M, et al. Tissue eosinophilia in acute and chronic atopic dermatitis:a morphometric approach using quantitative image analysis of immunostaining. Br J Dermatol. 2001;145:720–729. Epub 2001/12/12.
70. Salimi M, Barlow JL, Saunders SP, et al. A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis. J Exp Med. 2013;210:2939–2950. Epub 2013/12/11.
71. Laske N, Niggemann B. Does the severity of atopic dermatitis correlate with serum IgE levels? Pediatr Allergy Immunol. 2004;15:86–88. Epub 2004/03/05.
72. Katoh N, Hirano S, Kishimoto S. Prognostic factor of adult patients with atopic dermatitis. J Dermatol. 2008;35:477–483. Epub 2008/09/16.
73. Suarez-Farinas M, Dhingra N, Gittler J, et al. Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis. J Allergy Clin Immunol. 2013;132:361–370.
74. Jeong CW, Ahn KS, Rho NK, et al. Differential in vivo cytokine mRNA expression in lesional skin of intrinsic vs. extrinsic atopic dermatitis patients using semiquantitative RT-PCR. Clin Exp Allergy. 2003;33:1717–1724. Epub 2003/12/06.
75. MacGlashan DW, Jr., Bochner BS, Adelman DC, et al. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol (Baltimore, Md:1950). 1997;158:1438–1445. Epub 1997/02/01.
76. Haw S, Shin MK, Haw CR. The efficacy and safety of long-term oral cyclosporine treatment for patients with atopic dermatitis. Ann Dermatol. 2010;22:9–15. Epub 2010/06/16.
77. Pacor ML, Di Lorenzo G, Martinelli N, et al. Comparing tacrolimus ointment and oral cyclosporine in adult patients affected by atopic dermatitis:a randomized study. Clin Exp Allergy. 2004;34:639–645.
78. Haeck IM, Knol MJ, Ten Berge O, et al. Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis:a randomized controlled trial. J Am Acad Dermatol. 2011;64:1074–1084.
79. Hijnen D, De Bruin-Weller M, Oosting B, et al. Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell- attracting chemokine (CTACK) levels in allergic diseases:TARC and CTACK are disease-specific markers for atopic dermatitis. J Allergy Clin Immunol. 2004;113:334–340.
80. Jahnz-Rozyk K, Targowski T, Paluchowska E, et al. Serum thymus and activation-regulated chemokine, macrophage-derived chemokine and eotaxin as markers of severity of atopic dermatitis. Allergy. 2005;60:685–688.
81. Kakinuma T, Nakamura K, Wakugawa M, et al. Thymus and activation-regulated chemokine in atopic dermatitis:serum thymus and activation-regulated chemokine level is closely related with disease activity. J Allergy Clin Immunol. 2001;107:535–541.
82. Schneider L, Tilles S, Lio P, et al. Atopic dermatitis:a practice parameter update 2012. J Allergy Clin Immunol. 2013;131:295-9.e1-27. Epub 2013/02/05.
83. Seale JP, Compton MR. Side-effects of corticosteroid agents. Med J Aust. 1986;144:139–142.
84. Nesbitt LT, Jr. Minimizing complications from systemic glucocorticosteroid use. Dermatol Clin. 1995;13:925–939.
85. Schmitt J, Schmitt N, Meurer M. Cyclosporin in the treatment of patients with atopic eczema - a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2007;21:606–619. Epub 2007/04/24.
86. Hanifin JM, et al. Randomized, double-blind, placebo-controlled, multicenter, multidose phase II study of anti-interleukin-31 receptor A monoclonal antibody CIM331 (nemolizumab) in patients with moderate to severe atopic dermatitis. 2016. Late-breaking Abstract Session F053:JAAD.
87. Hamilton JD, Suarez-Farinas M, Dhingra N, et al. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2014;134:1293–1300.
88. Grunewald SM, Werthmann A, Schnarr B, et al. An antagonistic IL-4 mutant prevents type I allergy in the mouse:inhibition of the IL-4/IL-13 receptor system completely abrogates humoral immune response to allergen and development of allergic symptoms in vivo. J Immunol (Baltimore, Md:1950). 1998;160:4004–4009.
89. Popovic B, Breed J, Rees DG, et al. Structural characterisation reveals mechanism of IL-13-neutralising monoclonal antibody tralokinumab as inhibition of binding to IL-13Rα1 and IL-13Rα2. J Mol Biol. 2017;429:208–219.• Structural analysis showing that tralokinumab prevents IL-13 binding from both IL-13 receptors.
90. Ist Quarter Res. AstraZeneca; 2015. Available from:https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-plc-first-quarter-results-2015-24042015.html
91. Simpson E. Effiacy and safety of lebrikizumab in patients with atopic dermatitis:a Phase 2 randomized, controlled trial (TREBLE). Vienna, Austria:Publisher; 2016.
92. Van Der Hulst AE, Klip H, Brand PL. Risk of developing asthma in young children with atopic eczema:a systematic review. J Allergy Clin Immunol. 2007;120:565–569. Epub 2007/07/28.
93. Spergel JM. From atopic dermatitis to asthma:the atopic march. Ann Allergy Asthma Immunol. 2010;105:99-106;quiz 7-9, 17. Epub 2010/08/03.
94. Control CoD., Asthma Prevalence in the US 2016. Available from:https://www.cdc.gov/asthma/asthmadata.htm.
95. To T, Stanojevic S, Moores G, et al. Global asthma prevalence in adults:findings from the cross-sectional world health survey. BMC Public Health. 2012;12:204. Epub 2012/03/21.
96. Global Strategy for Asthma Management and Prevention (Revised 2016). Global Initiative for Asthma; 2016. Available from:ginasthma.org/wp-content/uploads/2016/04/GINA-2016-main-report_tracked.pdf
97. Wenzel S. Mechanisms of severe asthma. Clin Exp Allergy. 2003;33:1622–1628.
98. Bentley AM, Menz G, Storz C, et al. Identification of T lymphocytes, macrophages, and activated eosinophils in the bronchial mucosa in intrinsic asthma. Relationship to symptoms and bronchial responsiveness. Am J Respir Crit Care Med. 1992;146:500–506.
99. Ying S, Humbert M, Barkans J, et al. Expression of IL-4 and IL-5 mRNA and protein product by CD4+ and CD8+ T cells, eosinophils, and mast cells in bronchial biopsies obtained from atopic and nonatopic (intrinsic) asthmatics. J Immunol (Baltimore, Md:1950). 1997;158:3539–3544. Epub 1997/04/01.
100. Pelaia G, Vatrella A, Maselli R. The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012;11:958–972. Epub 2012/12/01.
101. Oh CK, Geba GP, Molfino N. Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma. Eur Respir Rev. 2010;19:46–54. Epub 2010/10/20.
102. Doherty T, Broide D. Cytokines and growth factors in airway remodeling in asthma. Curr Opin Immunol. 2007;19:676–680. Epub 2007/08/28.
103. Grunig G, Warnock M, Wakil AE, et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science. 1998;282:2261–2263.
104. Hahn C, Teufel M, Herz U, et al. Inhibition of the IL-4/IL-13 receptor system prevents allergic sensitization without affecting established allergy in a mouse model for allergic asthma. J Allergy Clin Immunol. 2003;111:1361–1369. Epub 2003/06/06.
105. Borish LC, Nelson HS, Lanz MJ, et al. Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. Am J Respir Crit Care Med. 1999;160:1816–1823.
106. Maes T, Joos GF, Brusselle GG. Targeting interleukin-4 in asthma:lost in translation? Am J Respir Cell Mol Biol. 2012;47:261–270.
107. Anderson GP. Endotyping asthma:new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet. 2008;372:1107–1119. Epub 2008/09/23.
108. Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med. 2008;178:218–224. Epub 2008/05/16.
109. Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med. 2010;181:315–323. Epub 2009/11/07.• A cluster analysis of various demographic and clinical variables of asthmatics revealed a subsets of asthma with shared several disease characteristics and common inflammatory patterns.
110. Woodruff PG, Modrek B, Choy DF, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med. 2009;180:388–395. Epub 2009/06/02.• Gene expression profiling of airway epithelial cells of asthmatics revealed molecular subgroups of asthma with common inflammatory patterns.
111. Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009;360:985–993.• This study demonstrated efficacy of anti-IL-5 in severe asthma patients with high sputum eosinophils.
112. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360:973–984.• This study demonstrated efficacy of anti-IL-5 in severe asthma patients with high sputum eosinophils.
113. Parulekar AD, Atik MA, Hanania NA. Periostin, a novel biomarker of TH2-driven asthma. Curr Opin Pulm Med. 2014;20:60–65. Epub 2013/11/20.
114. Takayama G, Arima K, Kanaji T, et al. Periostin:a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. J Allergy Clin Immunol. 2006;118:98–104. Epub 2006/07/04.
115. Hanania NA, Noonan M, Corren J, et al. Lebrikizumab in moderate-to-severe asthma:pooled data from two randomised placebo-controlled studies. Thorax. 2015;70:748–756. Epub 2015/05/24.•• Pooled analysis of replicate asthma trials (LUTE and VERSE) showing that lebrikizumab reduced asthma exacerbations in patients with high periostin levels.
116. Nicola A, Hanania M, Korenblat P, et al. LAVOLTA I and II:design and baseline characteristics of two phase III, randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of lebrikizumab in adult patients with uncontrolled asthma. 2016. ATS:Abstract A31.
117. Piper E, Brightling C, Niven R, et al. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Respir J. 2013;41:330–338. Epub 2012/06/30.•• Results from Phase 2a clinical study showing that 13 week of anti-IL-13 treatment with tralokinumab did not improve asthma control questionnaire in patients with moderate to severe asthma.
118. Juniper EF, Svensson K, Mork AC, et al. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med. 2005;99:553–558.
119. Fokkens WJ, Lund VJ, Mullol J, et al. EPOS 2012:European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology. 2012;50:1–12.
120. Klossek JM, Neukirch F, Pribil C, et al. Prevalence of nasal polyposis in France:a cross-sectional, case-control study. Allergy. 2005;60:233–237. Epub 2005/01/14.
121. Shashy RG, Moore EJ, Weaver A. Prevalence of the chronic sinusitis diagnosis in Olmsted County, Minnesota. Arch Otolaryngol Head Neck Surg. 2004;130:320–323. Epub 2004/03/17.
122. Alobid I, Cardelus S, Benitez P, et al. Persistent asthma has an accumulative impact on the loss of smell in patients with nasal polyposis. Rhinology. 2011;49:519–524. Epub 2011/11/30.
123. Van Zele T, Gevaert P, Holtappels G, et al. Oral steroids and doxycycline:two different approaches to treat nasal polyps. J Allergy Clin Immunol. 2010;125:1069–76e4. Epub 2010/05/11.
124. Musy PY, Kountakis SE. Anatomic findings in patients undergoing revision endoscopic sinus surgery. Am J Otolaryngol. 2004;25:418–422. Epub 2004/11/18.
125. Van Cauwenberge P, Van Hoecke H, Bachert C. Pathogenesis of chronic rhinosinusitis. Curr Allergy Asthma Rep. 2006;6:487–494. Epub 2006/10/20.
126. Van Zele T, Claeys S, Gevaert P, et al. Differentiation of chronic sinus diseases by measurement of inflammatory mediators. Allergy. 2006;61:1280–1289. Epub 2006/09/28.
127. Riechelmann H, Deutschle T, Rozsasi A, et al. Nasal biomarker profiles in acute and chronic rhinosinusitis. Clin Exp Allergy. 2005;35:1186–1191. Epub 2005/09/17.
128. Gevaert P, Calus L, Van Zele T, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol. 2013;131(110–6):e1.
129. Gevaert P, Van Bruaene N, Cattaert T, et al. a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol. 2011.
130. Asher MI, Montefort S, Bjorksten B, et al.; Group IPTS. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood:ISAAC phases one and three repeat multicountry cross-sectional surveys. Lancet. 2006;368:733–743.
131. Pawankar R, Canonica G, Holgate S, et al. WAO White Book on Allergy World Allergy Organization. 2011. Available from:http://www.worldallergy.org/UserFiles/file/WAO-White-Book-on-Allergy_web.pdf
132. Platts-Mills TA. The allergy epidemics:1870-2010. J Allergy Clin Immunol. 2015;136:3–13. Epub 2015/07/07.
133. Martino DJ, Saffery R, Allen KJ, et al. Epigenetic modifications:mechanisms of disease and biomarkers of food allergy. Curr Opin Immunol. 2016;42:9–15. Epub 2016/10/30.
134. Harb H, Renz H. Update on epigenetics in allergic disease. J Allergy Clin Immunol. 2015;135:15–24. Epub 2015/01/09.